106 related articles for article (PubMed ID: 29188776)
1. Metal complexes of isonicotinylhydrazide and their antitubercular activity.
Ali M; Ahmed M; Hafiz S; Kamal M; Mumtaz M; Hanif M; Khan KM
Pak J Pharm Sci; 2017 Nov; 30(6(Supplementary)):2399-2403. PubMed ID: 29188776
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
3. Antitubercular activity of Ru (II) isoniazid complexes.
Aguiar Id; Tavares A; Roveda AC; da Silva AC; Marino LB; Lopes ÉO; Pavan FR; Lopes LG; Franco DW
Eur J Pharm Sci; 2015 Apr; 70():45-54. PubMed ID: 25638418
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
5. Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis.
Barbosa AR; Caleffi-Ferracioli KR; Leite CQ; García-Ramos JC; Toledano-Magaña Y; Ruiz-Azuara L; Siqueira VL; Pavan FR; Cardoso RF
Chemotherapy; 2016; 61(5):249-55. PubMed ID: 26950478
[TBL] [Abstract][Full Text] [Related]
6. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB.
El-Sayed Zaki M; Goda T
Tuberculosis (Edinb); 2007 Mar; 87(2):102-8. PubMed ID: 17035089
[TBL] [Abstract][Full Text] [Related]
7. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
[TBL] [Abstract][Full Text] [Related]
8. Development of a three component complex to increase isoniazid efficacy against isoniazid resistant and nonresistant Mycobacterium tuberculosis.
Manning T; Plummer S; Baker T; Wylie G; Clingenpeel AC; Phillips D
Bioorg Med Chem Lett; 2015 Oct; 25(20):4621-7. PubMed ID: 26341133
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial Activity of combinatorial treatments composed of transition-metal/antibiotics against Mycobacterium tuberculosis.
Montelongo-Peralta LZ; León-Buitimea A; Palma-Nicolás JP; Gonzalez-Christen J; Morones-Ramírez JR
Sci Rep; 2019 Apr; 9(1):5471. PubMed ID: 30940878
[TBL] [Abstract][Full Text] [Related]
11. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
[TBL] [Abstract][Full Text] [Related]
12. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
[TBL] [Abstract][Full Text] [Related]
13. Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity.
Ruiz P; Rodríguez-Cano F; Zerolo FJ; Casal M
Microb Drug Resist; 2003; 9(3):313-6. PubMed ID: 12959411
[TBL] [Abstract][Full Text] [Related]
14. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
[TBL] [Abstract][Full Text] [Related]
15. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of multidrug-resistant Mycobacterium tuberculosis using the mycobacteria growth indicator tube (MGIT) system.
Telles MA; Bori A; Amorim AB; Cruz AF; Pini MI; Sato DN
Braz J Med Biol Res; 2002 Oct; 35(10):1127-31. PubMed ID: 12424483
[TBL] [Abstract][Full Text] [Related]
18. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.
Rodrigues L; Machado D; Couto I; Amaral L; Viveiros M
Infect Genet Evol; 2012 Jun; 12(4):695-700. PubMed ID: 21871582
[TBL] [Abstract][Full Text] [Related]
19. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
20. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
Johansen IS; Thomsen VØ; Marjamäki M; Sosnovskaja A; Lundgren B
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):103-7. PubMed ID: 15474318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
